Editas Medicine Announces Second Quarter 2025 Results and Business Updates GlobeNewswire August 12, 2025 Company to select lead development candidate in September; on track to file IND by mid-2026 and achieve human proof-of-concept by year-end 2026 First IND/CTA accepted for CD19 HD Allo CAR T program as part of collaboration with Bristol Myers Squibb, triggering […]

Nkarta Reports Second Quarter 2025 Financial Results and Corporate Highlights GlobeNewswire August 12, 2025 Initial update for NKX019 in multiple autoimmune indications expected in second half of 2025 Cash balance of $334.0 million on June 30, 2025, including cash, cash equivalents and investments, expected to fund operations into 2029 SOUTH SAN FRANCISCO, Calif., Aug. 12,

Erasca Reports Second Quarter 2025 Business Updates and Financial Results GlobeNewswire August 12, 2025 Efficient execution accelerated clinical entry of pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 Phase 1 monotherapy data for RAS-targeting franchise expected in 2026 Robust balance sheet with cash, cash equivalents, and marketable securities of $387 million as of June 30,

FormFactor, Inc. Announces CFO Transition GlobeNewswire August 12, 2025 LIVERMORE, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) — FormFactor, Inc. (Nasdaq: FORM) (the “Company” or “FormFactor”) today announced that Aric McKinnis, currently its Vice President and Corporate Controller, has been appointed to serve as the Company's new Senior Vice President and Chief Financial Officer. He succeeds

ProKidney Reports Second Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates GlobeNewswire August 12, 2025 FDA confirmed at a July 2025 Type B meeting and in the subsequent meeting minutes that eGFR slope is an acceptable surrogate endpoint for accelerated approval of rilparencel in patients with type 2 diabetes and advanced CKD; FDA

LAKE ELMO, Minn., Aug. 12, 2025 (GLOBE NEWSWIRE) — Pathway Health, a leading provider of health care consulting services, interim and permanent leadership, technology implementation, and training solutions, has been recognized as a 2025 Minnesota Star Tribune National Standard Top Workplace for the third consecutive year. The Top Workplaces program honors organizations that foster supportive,

Compass Therapeutics Announces Proposed Public Offering GlobeNewswire August 12, 2025 BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) — Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the launch of an underwritten public offering of its common stock and, in lieu of common

(NASDAQ:MDAI),(NASDAQ:MDAIW), Q2 Overview Research & Development Revenue of $5.1 Million, total revenue for the first half of 2025 of $11.8 Million Strong Cash position of $10.5 Million Submission of De Novo application to FDA completed in Second Quarter of 2025 DALLAS, Aug. 12, 2025 (GLOBE NEWSWIRE) — Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or

Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business Update GlobeNewswire August 12, 2025 PIVOT-PO Phase 3 trial evaluating tebipenem Hbr in complicated urinary tract infection (cUTI) patients stopped early for efficacy following review by independent data monitoring committee (IDMC) Spero, along with its development partner, GSK, plans to submit data from

(TSX:EDT), Results exceed prespecified primary endpoint of 95% posterior probability of benefit for PMX on 28-day mortality Pooled absolute risk reduction of 8.3%; Relative risk reduction of 18% Key secondary endpoint: 90-day Mortality 17.4% lower with PMX and >99% posterior probability of benefit 38.7% Mortality at 28 days with PMX confirms results of prior trial